*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.
GEN’s editor in chief, John Sterling, interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.
A discovery made by researchers at McGill University and the affiliated Lady Davis Research Institute for Medical Research at Montreal's Jewish General Hospital appears to offer new hope for the early diagnosis and treatment of Alzheimer's disease. The scientists report in the May 15 issue of the Journal of Biological Chemistry that the addition of a single phosphate to an amino acid in a key brain protein is a principal cause of Alzheimer's. Identifying this phosphate, one of up to two-dozen such molecules, could make earlier diagnosis of Alzheimer's possible and might, in the longer term, lead to the development of drugs to block its onset, according to the investigators.
During this week's podcast, Dr. Hemant Paudel, one of the study's main authors, talks about the tau protein and its relationship to the brain and central nervous system and discusses the link between an abnormally phosphorylated tau protein and Alzheimer's. He provides the details of his group's research project and points out what the team was able to clearly demonstrate. Dr. Paudel reveals what he believes will be the major impact of his Alzheimer's study and goes over the plans for the next phase of this research.
Hemant K. Paudel, Ph.D. is an Associate Professor in the Department of Neurology and Neurosurgery at McGill University, and Project Director at the Bloomfield Center for Research in Aging at Lady Davis Institute for Medical Research at The Sir Mortimer B. Davis-Jewish General Hospital.